275 Manufacture of allogeneic, HLA-matched, TCR-edited T-cell therapy reactive against minor histocompatibility antigen 1 to treat acute myeloid leukemia in combination with CD34 HSCT with the potential for high potency and durability
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.